Bioquell highlights suitability of Qube aseptic workstation

The UK-based company, who provide solutions to reduce risk of bio-contamination, recently highlighted the suitability of its workstations to the CAR-T therapy sector

Bioquell Qube aseptic workstation

Bioquell, headquartered in Hampshire, is a global expert in reducing the risk of bio-contamination in the life sciences market. Recently it announced its newly adapted modular isolator's suitability to the needs of the gene and cell therapy marketplace.

The Bioquell Qube aseptic workstation is the only modular isolator to offer built in Bioquell hydrogen peroxide vapour technology for rapid bio-decontamination, reduced risk and cost benefit, the isolator can be customised to suit the individual needs of cell therapy development companies, hospitals and service providers.

Because the needs of companies can expand or shift at any time and production is expensive, the Bioquell Qube offers a flexible option to grow, while avoiding the expense and time of custom stainless steel isolators.

Bioquell’s isolator technology can be applied to the critical nature of CAR-T, gene and cell therapy, helping to reduce the potential risk of contamination by microorganisms or another patient’s cells through product handling and environmental exposure.

With operators able to sit at the Qube work station, the process can be carried out within a guaranteed safe and productive ISO 5/EU Grade A environment, providing an added level of protection from potentially costly and hazardous bio-contamination.

The Qube’s design provides an effective aseptic environment from research & development through to the manufacturing process. The system reduces risk and supports biologics manufacturing expansion, which potentially enables more patients to be treated at the same time.

The Qube offers up to three chambers (two gloves in each) with optional material pass-throughs and rapid transfer ports (RTP) designed to meet workflow needs. It enables decontamination of materials in one chamber whilst operatives work in another and offers aseptic-hold retention for typically seven days depending on protocols.

Companies